Exploring the Natural and Treatment History of Vitiligo: Findings from the Global VALIANT Study

Kristen Bibeau, PhD, MSPH; Davinder Parsad, MD; John E. Harris, MD, PhD; Yan Valle, MSc, MBA; Mukta Tulpule, MBBS; Gaone Thihong Matewa, BBA; Christine LaFiura, BA; Anouk Lindley, MBA; Khaleb Ezzedine, MD, PhD

Introduction

Vitiligo is a chronic autoimmune disease characterized by the destruction of melanocytes, resulting in pale or white patches of skin. 

Methods

Study Design and Patients

The cross-sectional online survey recruited adult patients (aged ≥18 years) diagnosed with vitiligo by a healthcare professional.

Results

Patient Demographics

- Most patients reported slow progression (36.0%) or rapid progression (31.9%)
- Most patients (68.7%) were hopeful that a new treatment will become available.
- Significantly higher rates of flares during periods of stress were reported by patients with higher BSA involvement.

Disease Characteristics

- Median (IQR) BSA affected by vitiligo was 4.23% (0.00%–73.8%), as measured for the 4573 participants (Table 2).
- Most (83.6%) reported experiencing flares during periods of stress.

Treatment History and Satisfaction

- Patients used a mean (SD) of 5.8 (2.5) treatments to manage their vitiligo.

Conclusions

- Globally, 14.1% of patients were not actively using treatment, with significantly higher rates in Brazil (21%) and 31.7% of patients compared with other regions.

Disclosures


- KE is a consultant for AbbVie, to disclose. GTM is the founder of Beyond Vitiligo South Africa and cofounder of Beyond Vitiligo Botswana. CL is a co-owner of Villaris Therapeutics; and has patents pending for IL-15 blockade for treatment of vitiligo, JAK inhibition with light therapy for vitiligo, EMD Serono, Genzyme/Sanofi, Incyte Corporation, Pfizer, and Sun Pharmaceuticals. JEH has served as a consultant for AbbVie, Aclaris Therapeutics, BiologicsMD, EMD Serono, Genzyme/Sanofi, Incyte Corporation, Pfizer, and Sun Pharmaceuticals. JEH has served as a consultant for AbbVie, Aclaris Therapeutics, BiologicsMD, EMD Serono, Genzyme/Sanofi, Incyte Corporation, Pfizer, and Sun Pharmaceuticals.

- KE is a consultant for AbbVie, to disclose. GTM is the founder of Beyond Vitiligo South Africa and cofounder of Beyond Vitiligo Botswana. CL is a co-owner of Villaris Therapeutics; and has patents pending for IL-15 blockade for treatment of vitiligo, JAK inhibition with light therapy for vitiligo, EMD Serono, Genzyme/Sanofi, Incyte Corporation, Pfizer, and Sun Pharmaceuticals. JEH has served as a consultant for AbbVie, Aclaris Therapeutics, BiologicsMD, EMD Serono, Genzyme/Sanofi, Incyte Corporation, Pfizer, and Sun Pharmaceuticals.


- KE is a consultant for AbbVie, to disclose. GTM is the founder of Beyond Vitiligo South Africa and cofounder of Beyond Vitiligo Botswana. CL is a co-owner of Villaris Therapeutics; and has patents pending for IL-15 blockade for treatment of vitiligo, JAK inhibition with light therapy for vitiligo, EMD Serono, Genzyme/Sanofi, Incyte Corporation, Pfizer, and Sun Pharmaceuticals. JEH has served as a consultant for AbbVie, Aclaris Therapeutics, BiologicsMD, EMD Serono, Genzyme/Sanofi, Incyte Corporation, Pfizer, and Sun Pharmaceuticals.